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Although liver biopsy is an invasive procedure, it remains the gold standard technique for the evaluation of
hepatic ﬁbrosis in different patients, including those with major thalassemia (MT). Recently, noninvasive
imaging techniques, such as transient elastography, have emerged. We investigated the effectiveness of TE, in
comparison to liver biopsy, for the evaluation of liver ﬁbrosis in pediatric patients with MT who were can-
didates for hematopoietic stem cell transplantation (HSCT). Eighty-three pediatric MT patients (48 boys and
35 girls), who were candidates for HSCT, were included in this study. The median age was 8 years. Liver
stiffness was assessed for all patients, before transplantation, using both TE, measured in kilopascals (kPa) and
liver biopsy, based on the Metavir score. The diagnostic accuracy of TE and liver biopsy were estimated using
linear discriminated analysis (the area under the receiver operating characteristic curves [AUROCs]). The
median TE score was 4.3 kPa (range, 3.5 to 5.2). The TE value did not differ among patients with different
ferritin levels (P ¼ .53). TE increased proportionally to Metavir ﬁbrosis stages (P < .001) and the necro-
inﬂammatory grade (P < .001). The TE score also correlated to liver iron content (P < .001), liver size
(P < .003), and Lucarelli risk classiﬁcation (LRC) (P < .001). ROC curve analysis revealed moderate accuracy of
the TE score for the diagnosis of ﬁbrosis (AUROC ¼ 73%) and for distinguishing individuals with a LRC III from
those classiﬁed as I and II (AUROC ¼ 82%). The TE score was also superior to Fibrosis-4 (AUROC ¼ 61%) for the
assessment of liver ﬁbrosis and LRC differentiation. The results of this study demonstrated that TE can be a
valuable method for assessing liver ﬁbrosis and differentiating LRC III from the other 2 classes in pediatric
patients with MT who have been selected for HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Major thalassemia (MT), 1 of the most common genetic
disorders worldwide [1,2], results from inadequate produc-
tion or the absence of the beta chain of hemoglobin [3,4].
Although noncurative medical treatment has trans-
formed MT from a lethal disease of childhood to a chronic
disease of adulthood, hematopoietic stem cell trans-
plantation (HSCT), with a high probability of event-free
survival (80%) is currently the only curative treatment for
MT patients [5e7]. However, HSCT is associated with the riskedgments on page 1917.
quests: Hossein Poustchi, MD, PhD, Liver
er, Digestive Diseases Research Institute,
es, Kargar Ave. Tehran, Iran, 14117-13135.
ail.com (H. Poustchi).
14.07.025
ty for Blood and Marrow Transplantation.of transplantation-related mortality, graft-versus-host dis-
ease, and graft failure; therefore, selecting optimal trans-
plantation candidates is extremely crucial. Also, considering
the fact that MT patients are predisposed to liver ﬁbrosis as a
consequence of multiple blood transfusions, it is of utmost
importance to classify the patients using the Lucarelli risk
classiﬁcation (LRC) before HSCT so that each patient will
receive the appropriate conditioning regimen based on this
classiﬁcation. The LRC, which was ﬁrst described in the late
1980s, is used as a prognostic system to predict trans-
plantation outcomes in MT patients [8]. This classiﬁcation
consists of 3 risk factors: the quality of chelation therapy
during the years before transplantation, hepatomegaly
(>2 cm below the intercostal margin), and the presence of
any portal ﬁbrosis in the pretransplantation liver biopsy
[7e9]. It is very important to use LRC before HSCT, as
Table 1
Characteristics of Patients
Variable Value
Age, yr 8 (5-11)
Gender 48 male, 35 female
BMI (kg/m2) 14.7 (13.8-16.1)
Ferritin (ng/mL) 1764 (1000-2311)
ALT (IU/L) 24 (15-36)
AST (IU/L) 28 (22-35)
ALP (IU/L) 396 (317-490)
Bilirubin total (mg/dL) 1.5 (.9-1.9)
Bilirubin direct (mg/dL) .4 (.2-.5)
Prothrombin time (sec) 13.4 (12-14)
Albumin (g/dL) 3.9 (3.5-4)
TE scores (kPa) 4.3 (3.5-5.2)
METAVIR stage, n (%)
F0 (no ﬁbrosis) 14 (16.9)
F1 (portal ﬁbrosis without septa) 50 (60.2)
F2 (portal ﬁbrosis with few septa) 7 (8.4)
F3 (numerous septa without cirrhosis) 12 (14.4)
F4 (cirrhosis) 0
METAVIR grade, n (%)
A0 (no activity) 65 (78.31)
A1 (mild activity) 18 (21.69)
A2 (moderate activity) 0
A3 (severe activity) 0
Iron load by atomic absorption
spectrometry,  times more than normal
9 (5-15.7)
Liver size, mm 111 (100-130)
LRC, n (%)
1 15 (18.1)
2 46 (55.4)
3 22 (26.5)
ALP indicates alkaline phosphatase.
Date presented as median (IQR) or n (%), as appropriate.
Figure 1. Correlations of TE score with METAVIR stage of ﬁbrosis.
A.A. Hamidieh et al. / Biol Blood Marrow Transplant 20 (2014) 1912e1917 1913conditioning regimens and prognosis of this procedure are
not the same in LRC class III patients and for those who fall
into class I or II [8,10].
Although liver biopsy remains a gold standard for evalu-
ating hepatic ﬁbrosis, which is needed to determine the LRC,
the invasiveness of biopsy and its related complications in
MT patients have necessitated the application of novel,
validated, noninvasive modalities for estimating the stage of
hepatic ﬁbrosis [4,11]. Several approaches, such as the
Fibrosis-4 (FIB-4), the Lok index, the Fibro test, and the
aspartate aminotransferase (AST)-to-platelet ratio index
(APRI), have been used by investigators and compared with
liver biopsy, showing varying degrees of accuracy in evalu-
ating liver ﬁbrosis. Another approach, transient elastography
(TE), has also been used as a reliable, noninvasive tool for
evaluating liver ﬁbrosis, showing comparable results to liver
biopsy, especially in patients with chronic viral hepatitis and
cirrhosis [12,13]. However, studies on TE’s performance
assessing liver ﬁbrosis in MT patients and especially its
impact on determining the LRC are still scarce in the litera-
ture [14,15].
This study has 2 aims. The ﬁrst is to investigate the efﬁcacy
of TE for the evaluation of liver ﬁbrosis, compared with liver
biopsy, in MT patients selected for HSCT. The second aim is to
evaluate the predictive accuracy of TE in distinguishing MT
patients characterized as LRC class III from the others.
METHODS
Participants and Study Design
Pediatric transplantation candidates diagnosed with MT who were
referred to Shariati Hospital from October 2010 to February 2012 were
enrolled in this study. A written informed consent was obtained from every
patient’s parents or legal guardians. Patients who did not give consent
received the routine clinical care at our center. The study protocol was in
accordance to the guidelines of the Declaration of Helsinki and was
approved by the ethics committees of the Hematology-Oncology Research
Center and Stem Cell Transplantation and the Digestive Diseases Research
Institute.
Hemoglobin electrophoresis or mutation analyses were performed on
all patients to conﬁrm the diagnosis of MT. Patients with cardiovascular
diseases; cirrhosis; human immunodeﬁciency virus; viral hepatitis,
including hepatitis B or hepatitis C; and any other chronic liver disease were
excluded from the study. All patients underwent both a liver biopsy (before
transplantation) and TE with a maximum interval of 3 months between the
2 procedures. The same individual performed all TE examinations in the 83
patients. The TE operator, as well as the gastroenterologist performing the
biopsy, were blinded to the results of the other procedure. Laboratory
evaluations including a complete blood count and platelet counts, as well as
serum ferritin, AST, alanine aminotransferase (ALT), alkaline phosphatase,
bilirubin (total and direct), albumin levels, and coagulation tests such as
partial prothrombin time (PTT), prothrombin time (PT), international
normalized ratio (INR) and bleeding time (BT), were measured in all
patients.
All patients were classiﬁed based on the following LRC criteria: the
quality of chelation therapy given before HSCT, the presence of hepato-
megaly (palpable liver more than 2 cm below the costal margin), and the
presence of any portal ﬁbrosis on biopsy. Regular chelation therapy was
deﬁned as the use of deferoxamine 40 mg/kg for 8 to 12 hours each day, at
least 5 days a week, starting less than 2 years from the time blood trans-
fusions started. The absence of hepatomegaly and liver ﬁbrosis, along with
regular iron chelation before transplantation, categorizes an individual as
class I, presenting with 1 or 2 of the 3 criteria deﬁnes class II, and having all 3
criteria characterizes class III [7e9].
Transient Elastography
TE was performed using Fibroscan502 (5 MHz, EchoSens, Paris, France).
The S andM probes were used based on themanufacturer’s guidelines: the S
probe was used when the thoracic parameter was 75 cm, and the M probe
was used when the thoracic parameter was >75 cm. With the patient lying
in a dorsal decubitus position, and with maximal abduction of the right arm,
the probe was placed on the patient’s skin, overlying the right lobe of the
liver, through the intercostal spaces. The median value of 10 valid mea-
surements was recorded for each subject. The recorded value wasconsidered valid if the interquartile range (IQR) was less than 30% of the
median reading. The results were presented in kiloPascals (kPa).
Liver Biopsy
Liver biopsy samples were obtained before transplantation, using a 16-
gauge AceCut biopsy needle (TSK Laboratories, Tochigi-ken, Japan).
The biopsy specimens were considered adequate if they were at least
20 mm in length and contained 10 or more portal tracts. Fibrosis stage and
necro-inﬂammatory grades were scored, based on the METAVIR system, by
an expert liver pathologist.
Liver iron concentration (LIC) was quantiﬁed using atomic absorption
spectrometry (Varian SpectrAA 20, Belrose, Australia). The presence of any
ﬁbrosis on biopsy was considered as a risk factor for LRC.
FIB-4 and APRI were also compared to liver biopsy results. FIB-4, which
is based on simple variables such as age, AST, ALT, and platelet counts, was
calculated using the following formula: age (years) $ AST [U/L]/(platelets
[109/L](ALT [U/L])1/2), whereas APRI was calculated as (AST/upper limit of
normal range)/platelet count (109/L) $ 100.
Table 2
Spearman’s Rank Correlation Coefﬁcient between TE Values and Other
Variables
Variable Correlation
Coefﬁcient
P Value
Age (yr) .29 .007
Stage (METAVIR) .4 <.001
Grade (METAVIR) .48 <.001
LRC .5 <.001
Liver size, mm .44 .03
Iron load by atomic absorption
spectrometry
.42 <.001
BMI (kg/m2) .28 .01
AST (IU/L) .25 .05
ALT (IU/L) .31 .01
ALP (IU/L) .13 .32
Albumin (g/dL) .08 .53
Prothrombin time (sec) .04 .71
Bilirubin total (mg/dL) .05 .7
Bilirubin direct (mg/dL) .03 .82
Ferritin (ng/mL) .02 .87
AAR* .2 .09
FIB-4y .39 .002
Platelet (cumm) .27 .03
* AST to ALT ratio ¼ AST (IU/L)/ALT (IU/L).
y FIB-4 ¼ age (years)  AST (U/L)/(platelets [109/L]  ALT [U/L]1/2).
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used for statistical analysis. Because of the skew of the data, continuous
variables were presented as median (IQR) and categorical variables were
presented as frequency (%). Spearman’s rank correlation was used to eval-
uate the relationships between the TE score and other variables. Linear
regression models were used to assess the effect of clinical factors on the
inversed TE scores. Independent variables with P < .20 in simple regression
analysis were included in the multivariable model. Variance inﬂation factor
and correlation coefﬁcients were calculated to assess multicolinearity.
Receiver operating characteristics (ROC) curve analysis was undertaken to
evaluate the accuracy of TE to predict liver ﬁbrosis and to compare its ac-
curacy with FIB-4 [16,17]. To improve the predictive power of TE in combi-
nation with FIB-4 for the diagnosis of liver ﬁbrosis, we developed weighted
linear combinations based on the coefﬁcients obtained from the logistic
regression analysis, with liver ﬁbrosis (METAVIR F0 versus F1 and F2 and F3)
as the outcome variable and TE score and FIB-4 as predictors. The best cut-
off scores were chosen according to the Youden’s J index. P < .05 was
considered statistically signiﬁcant.Table 3
Results of Simple and Multivariable Regression Analysis for Finding Predictors of I
Variable Univariate Analysis
Unstandardized
Coefﬁcients
Age .006 (.31)
Gender (M/F) .01 (.09)
Stage (zero as reference)
F1 (METAVIR) .06 (.4)
F2 (METAVIR) .07 (.24)
F3 (METAVIR) .13 (.59)
Grade (A0/A1) .07 (.39)
LRC (I as reference)
II .03 (.17)
III .11 (.61)
Iron load by atomic absorption spectrometry .003 (.35)
ALT (IU/L) .001 (.16)
AST (IU/L) .0001 (.07)
ALP (IU/L) .00004 (.13)
BMI (kg/m2) .01 (.3)
PT (sec) .00001 (.001)
Bilirubin total (mg/dL) .004 (.047)
Bilirubin direct (mg/dL) .005 (.01)
Albumin (g/dL) .01 (.11)
Ferritin (ng/mL) .000002 (.05)
M indicates male; F, female; PT, prothrombin time.
Variance inﬂation factor for all variables is < 5, Adjusted R-squared: .3.RESULTS
Eighty-three (48 boys and 35 girls) pediatric MT patients
who were eligible for HSCT were included in this study.
Baseline clinical and laboratory ﬁndings are presented in
Table 1.
No patients were excluded from the study because of
abnormal coagulation tests. There were no major complica-
tions after liver biopsy, except the usual complications, such
as pain at the biopsy site.
Based on the biopsy results, the median LIC level was 9
times (IQR, 5 to 15.7) more than normal LIC levels, which
signiﬁcantly correlated with serum ferritin levels (r ¼ .29,
P ¼ .01). LIC differed signiﬁcantly among the different MET-
AVIR stages of ﬁbrosis (P ¼ .006). There was no correlation
between serum ferritin levels and stage of ﬁbrosis (r ¼ .11,
P ¼ .31).
All TE procedures were performed successfully, reaching
at least a 60% success rate and an IQR< 30% of the median TE
value for all patients. The median TE score was 4.3 kPa (IQR,
3.5 to 5.2). The TE values for patients with ferritin levels of <
500, 500 to 1000 and> 1000 ng/mLwere 4.5 (IQR, 3.5 to 4.5),
5.75 (IQR, 3 to 8.5), and 4.25 (IQR, 3.6 to 5), respectively.
These values were not signiﬁcantly different (P ¼ .53).
TE increased proportionally to METAVIR ﬁbrosis stages
(r ¼ .4, P < .001) and the necro-inﬂammatory grade (r ¼ .48,
P < .001) (Figure 1). The TE score also correlated with LIC
(r ¼ .42, P < .001), LRC (r ¼ .5, P < .001), and liver size in
millimeters (r ¼ .44, P < .03) (Table 2). Correlation co-
efﬁcients of the other variables are also listed in Table 2.
As shown in Table 3, age, ﬁbrosis stage, necro-
inﬂammatory grade, LRC, LIC, and body mass index (BMI)
were associated with the inversed TE score with P < .20, and
hence, were included in the multivariable model. In the
multivariable analysis, the inverse TE score was indepen-
dently associated with the ﬁbrosis stage (stage F1 METAVIR)
and the necro-inﬂammatory grade, but its association with
age, LRC, LIC, and BMI lost signiﬁcance (Table 3).
ROC curve analysis revealed moderate accuracy of the TE
score for the diagnosis of ﬁbrosis (area under ROC
[AUROC] ¼ 73%) (Table 4) and for distinguishing LRC class IIInversed TE (1/TE Score)
Multivariable Analysis
P Value Unstandardized
Coefﬁcients
P Value
.005 .003 (.17) .146
.43 - -
.005 .05 (.32) .023
.05 .04 (.13) .40
<.001 .03 (.12) .49
<.001 .08 (.44) .029
.2 .014 (.09) .55
<.001 .02 (.1) .56
.001 .001 (.16) .16
.21 - -
.58 - -
.32 - -
.007 .001 (.01) .92
.99 - -
.7 - -
.9 - -
.4 - -
.67 - -
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superior to FIB-4 (AUROC ¼ 61%) for the evaluation of liver
ﬁbrosis and the LRC (Table 4). Using the related coefﬁcients of
logistic regression analysis, the linear combination of TE-FIB-
4 score, calculated as TE score - (1.59  FIB-4) was able to
determine ﬁbrosis levels and distinguish LRC class III with
AUROC of 74% and 88%, respectively. The best cut-off values,
sensitivity, and speciﬁcity for TE, FIB-4, and TE-FIB-4 scores
are summarized in Table 4.
As shown in Figure 2, using 4.5 as the TE cut-off score, 20
(24.1%) of 83 patients were falsely classiﬁed as risk class III
(false positives). However, combining the predictive accuracy
of TE and FIB-4 resulted in the number of false positives to
decrease to 10 (12%). The number of patients falsely classiﬁed
as class I or II (false negatives) were 3 (3.6%) for both scores.
DISCUSSION
This study demonstrated that TE alone is moderately ac-
curate in detecting hepatic ﬁbrosis and differentiating the LRC
class III from the other 2 classes in pediatric MT patients less
than 12 years of age whowere selected for HSCT. TE showed a
higher accuracy in this regard when combined with FIB-4.
Contemporary achievements are of signiﬁcant impor-
tance because MT patients suffer from hepatic injury related
to iron overload as a consequence of multiple blood trans-
fusions, and although liver biopsy is considered to be the
gold standard for detecting liver ﬁbrosis, it imposes probable
complications on MT patients [13,14]. Additionally, it is very
important to accurately identify patients with an LRC score of
III because of the different conditioning regimens that are
used before transplantation, as well as the patient’s prog-
nosis after transplantation [4,15]. Thus, a noninvasive
method for the evaluation of liver damage in MT patients is
necessary. Although various studies have revealed satisfac-
tory results on the use of TE in assessing hepatic ﬁbrosis of
diverse etiologies, adequate information is not available
about its use in MT patients [12,15,18].
This study consisted of a relatively large sample size
(n ¼ 83), in which liver biopsy and the measurement of he-
patic iron load were performed in all participants. The results
demonstrated a direct correlation between the TE score and
ﬁbrosis stage as well as the necro-inﬂammatory grade, which
was in agreement with previous studies. In a study per-
formed by Fraquelli et al. [15], TE was applied for assessing
the degree of hepatic ﬁbrosis in 115 adult patients with
thalassemia and the results demonstrated that TE is a reliable
tool in detecting severe ﬁbrosis and cirrhosis in those pa-
tients. In another study by Poustchi et al. [13] involving 76
thalassemia patients with chronic hepatitis, the accuracy of
TE for the assessment of liver ﬁbrosis was evaluated. The
results demonstrated that regardless of LIC, TE alone or in
combination with FIB-4 or APRI possessed moderate to high
accuracy for the evaluation of liver ﬁbrosis in chronic hepa-
titis C patients with beta thalassemia, which supports the
ﬁndings of this study, as well.
In addition, the current study revealed that TE is much
more reliable than FIB-4 for the assessment of liver ﬁbrosis
and for the differentiation of LRC class III patients from
others. This may be due to the signiﬁcant correlation of the
TE scores with the liver size in this study, as hepatomegaly is
1 of the components of LRC.
To see if there is a more accurate and efﬁcient way of
assessing liverﬁbrosis and distinguishing among patientswith
a class III LRC score from the others, the FIB-4 and TE scores
were combined. This combination demonstrated improved
Predictive accuracy of TE score to differentiate Lucarelli risk class III from 
I & II
Predictive accuracy of TE-FIB4 fibrosis score to differentiate Lucarelli risk class III from
 I & II
Figure 2. Predictive accuracy of TE score alone or in combination with FIB-4 for differentiating Lucarelli risk class III from I and II. (A) The predictive accuracy of TE
scores to differentiate Lucarelli risk class III from I and II. (B) The predictive accuracy of TE-FIB4 ﬁbrosis score to differentiate Lucarelli risk class III from I and II.
A.A. Hamidieh et al. / Biol Blood Marrow Transplant 20 (2014) 1912e19171916performance in both mentioned ﬁelds. Using TE alone with a
cut-off of 4.5 kPa was capable of distinguishing TM class III
patients with a moderate-to-high degree of accuracy
(sensitivity ¼ 86.4%, speciﬁcity ¼ 67.8%), whereas using TE in
combination with the FIB-4 score with a cut-off of 4.34 kPa
demonstrated a great level of efﬁciency in detecting class III
patients (sensitivity¼ 84.2%, speciﬁcity¼ 83.3%). The foresaid
dataare inaccordancewithdata releasedbyPoustchi et al. [13].
Furthermore, contrary to previous studies, our analysis
revealed a signiﬁcant correlation between LIC and TE scores.
In a study performed by Di Marco et al. [12], the evaluation of
56 homozygous beta-thalassemic patients demonstrated no
correlation between hepatic iron content (also measured by
atomic absorption spectrometry) and TE scores, whereas an
increase in hepatic stiffness related to liver ﬁbrosis stage was
found. These differences may be due to the diversity of the
participants; although our study included pediatric patients
eligible for HSCT, the study by Di Marco et al. study
comprised a relatively heterogeneous group (45 adults and
11 children), of whom 41% were hepatitis C virus positive. In
the study by Fraquelli et al. [15], the limited number of par-
ticipants with liver biopsy prevented them from assessing
the inﬂuence of LIC on the TE score. In the study performed
by Poutchi et al., no correlation was demonstrated between
LIC (measured by T2*magnetic resonance imaging) or serumferritin and TE scores. These differences may be due to the
different methods applied to measure LIC. Although
measuring LIC using the atomic absorption spectrometry is
considered to be themost direct clinical method and the gold
standard, it may still be of low accuracy in small sample sizes
and because of uneven distribution of iron throughout the
liver. The occurrence of complications is inevitable after
performing liver biopsy because of its invasive nature
[16,17,19e22]. Other methods, for example, magnetic reso-
nance imaging, have also been demonstrated to be a bene-
ﬁcial, noninvasive, and relatively accurate method for the
measurement of LICs in vivo in a wide spectrum of hema-
tological and liver diseases [23].
To our knowledge, this is the ﬁrst study using TE in pe-
diatric patients speciﬁcally when patients with viral hepatitis
or any chronic liver diseases have been excluded; neverthe-
less, a small sample size is still a limitation of our study.
Additionally, despite being considered a novel noninvasive
method for detecting hepatic ﬁbrosis through measuring
liver stiffness [24], TE also has its own limitations. Two of the
most important problems that restrict its use are TE’s failure
in obese patients and also in patients with ascites [24], as
well as its overestimation of ﬁbrosis when the ALT levels are
high [25e27]. Fortunately, as our patients were children
under age 12, with relatively low BMIs (mean, 14.7), inwhom
A.A. Hamidieh et al. / Biol Blood Marrow Transplant 20 (2014) 1912e1917 1917ALT ﬂare before HSCT was absent, the TE results were not
largely affected by these restrictions, and consequently, no
cases of TE failure were reported.
In conclusion, our study demonstrated that TE may be
considered an alternative diagnostic tool with moderate to
high accuracy for the assessment of liver ﬁbrosis in pediatric
MT patients. In addition, higher accuracy is obtained by
combining TE scores with the FIB-4 to identify LRC class III
patients. Since liver biopsy cannot be performed frequently,
MT patients are not often studied in this regard after HCST,
and it seems that TE can be considered as an alternative
diagnostic technique for evaluating the liver status of TM
patients after transplantation.ACKNOWLEDGMENTS
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